28 May 2009
GW Pharmaceuticals has filed for approval of its cannabis-based drug for multipl sclerosis, Sativex in Spain and the UK.
If the drug, currently available in Canada, is approved, regulators would allow the drug to be marketed across Europe for all patients with spasticity, the involuntary spasms associated with MS.
"We are anticipating and outcome for that regulatory process around the end of this calendar year or early 2010 in the UK and Spain which would then lead to launches in those countries," commented Justin Gover, GW managing director. "Commercial sales of Sativex will start to have a meaningful impact on our business from next year onwards."
Sativex is made using two strains of cannabiss which GW bought from Dutch-based researchers Hortipharm more than a decade ago. The cannabis is grown under artificial lights at a secret location in the UK under a Home Offic licence, and then processed into a sticky molasses-like substance that is then further refined so it can be used in an oral spray.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.